– UK, London – ValiRx (LON: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today announced the appointment of Stella Panu to its Board as Non-executive Director with immediate effect.
“We are delighted to formally welcome Stella to the Board. I look forward to working closely with Stella, using her expertise to help guide the implementation of our growth strategy.” said CEO, Dr Suzy Dilly.
About Stella Panu
Stella Panu was a founding Partner of Maven Capital Partner UK LLP, an investment management company, created after a management buyout of the private equity business of Aberdeen Asset Management plc in 2009, and led the business through to its sale in July 2021. Maven has a focus on venture growth and innovation and during her time at Maven, Stella led the AIM Investment team and was the lead investor in private equity across Maven. Stella was recently appointed a Non-executive Director of Vianet Group plc, an international provider of actionable data and business insight through devices connected to its Internet of Things platform. Having previously been at AAM and Seymour Pierce Ltd and had seats on numerous company boards, Stella brings with her a wealth of private equity M&A and AIM experience.
Stella has also previously worked for Pricewaterhouse Coopers, The World Bank, and Raifessen Investment Fund and holds a Bachelor’s degree in Economics and an MA in Applied Economics and Statistics.
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling the rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx’s portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialization.
For more information: https://www.valirx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
